Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

GT Biopharma, Inc.GTBP · healthcare
GradeNonecomputable_factors_below_threshold: 2 of 14 inputs computable; 7 are required
Reliability0.76 AUCfailure model, filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate0.60% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size bandunder $12.5M assetstotal assets $8.1M[1]
Standard universeoutsiderevenue above $1M and assets above $10M[1-2]
Warningsdilution, short runway, thin data, degenerate inputsnot computable: distress, fortress balance sheet
Inputs computable2 of 14
Graded fromfilings received through Mar 2, 2026221 days before the rescan; every figure keyed to the SEC receipt date
Last close$6.222026-10-05; market equity $280.8M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$5$10NovDecJanFebMarAprMayJunJulAugSepOct$5.96
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Apr 21, 2012nonen/aQ1
Mar 21, 2018nonen/aQ3
Apr 21, 2019nonen/aQ2
Apr 21, 2020nonen/aQ1
Apr 21, 2023nonen/aQ2
Feb 21, 2025nonen/aQ1

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Mar 2, 2026; the document on sec.gov.

are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based on our proprietary Tri-specific Killer Engager (“TriKE®”), and Tetra-specific Killer Engager (“Dual Targeting TriKE®”) fusion protein immune cell engager technology platforms. Our TriKE® and Dual Targeting TriKE® platforms generate proprietary therapeutics designed to harness and enhance the cancer killing abilities of a patient’s own natural killer cells (“NK cells”).

Warnings [top]

Dilution. split-adjusted year-over-year share growth is 1312.2%[3-4]
Short runway. cash runway is 4.1 months[5]
Thin data. 2 of 14 grade factors are computable; minimum is 7
Degenerate inputs. latest revenue or assets are at or below the $100,000 validity floor[1-2]

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability
Gross profitabilitynot computable32.2%
latest aligned inputs end 2017-12-31; latest annual assets end 2025-12-31
Return on invested capitalnot computable9.3%
one or more required annual facts are missing
Accruals rationot computable(6.6%)
prior assets observation is 92 days earlier
Gross margin stability, five yearsnot computable2.8 pts
annual revenue must exceed $100,000
Solvency, sleeve percentile 52.0
Twelve-month failure probabilitynot computable0.07%
liabilities and a nearby cover-page share count are required at 2026-06-30
Altman Z double-primenot computable(0.31)
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Net debt to EBITDAnot computable1.82x
one or more required annual facts are missing
Interest coveragenot computable(4.51x)
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio3.50x[6-7]2.96x52.08392025-12-31
Growth and financing, sleeve percentile 97.0
Revenue growth, three-year compoundnot computable10.0%
four consecutive annual observations are required
Free cash flow growth, three-year compoundnot computable10.9%
current FCF must be positive and base FCF must exceed $100,000
Reinvestment ratenot computable37.1%
latest aligned inputs end 2019-12-31; latest annual assets end 2025-12-31
Asset growth, three yearsnot computable2.1%
four consecutive annual observations are required
Net share issuance, one year1,312.2%[3-4]2.5%97.06342026-02-23

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-05 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month1,119.1%8.0%100hotter than 100 of 100 peers
Distance from 52-week high(48.8%)(31.4%)29closer to its high than 29 of 100 peers
EBIT to enterprise valuenot computable(1.5%)required accounting or market input is missing
Free cash flow yield(1.4%)(1.0%)48pricier than 52 of 100 peers
Book value to price0.010.2814pricier than 86 of 100 peers
Sales to price0.000.310pricier than 100 of 100 peers
Composite equity issuance, five years386.4%20.3%97more equity-funded than 97 of 100 peers
Relative strength against the sector, log excess return2.29(0.14)100ahead of 100 of 100 peers

Inputs: market equity $268.9M; EBIT -$12.4M; free cash flow -$3.7M; book equity $3.6M; sales $0; cash $5.0M[8].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zeron/a
Operating cash flow above zero-$12.9M✗ fail[9]
Return on assets improvedn/a[10]
Operating cash flow exceeds net income$15.4M✓ pass[9-10]
Long-term leverage felln/a[1]
Current ratio improvedn/a[6-7]
No new shares issued1,312.2%✗ fail[3-4]
Gross margin improvedn/a
Asset turnover improvedn/a
Cash, filings, liquidity
Cash and equivalents$5.0M[5]
Operating cash flow, four quarters-$14.4M[5,9,11-14]
Months of runway4.1
Late filings, two years0
NT 10-K or NT 10-Q
Days since last periodic filing56
10-Q received Aug 14, 2026
Median daily dollar volume$177,206
63 sessions
Days since newest grade input221

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$8.1M2025-12-312026-03-0210-Kfiling · viewer · series
2revenueus-gaap:Revenues$02020-12-312021-04-1610-Kfiling · viewer · series
3shares outstandingdei:EntityCommonStockSharesOutstanding31,553,8922026-02-232026-03-0210-Kfiling · viewer · series
4shares outstandingdei:EntityCommonStockSharesOutstanding2,234,3282025-02-192025-04-1410-K/Afiling · viewer · series
5cashus-gaap:CashAndCashEquivalentsAtCarryingValue$5.0M2026-06-302026-08-1410-Qfiling · viewer · series
6current assetsus-gaap:AssetsCurrent$8.1M2025-12-312026-03-0210-Kfiling · viewer · series
7current liabilitiesus-gaap:LiabilitiesCurrent$2.3M2025-12-312026-03-0210-Kfiling · viewer · series
8shares outstandingdei:EntityCommonStockSharesOutstanding45,109,4972026-08-102026-08-1410-Qfiling · viewer · series
9operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$12.9M2025-12-312026-03-0210-Kfiling · viewer · series
10net incomeus-gaap:NetIncomeLoss-$28.4M2025-12-312026-03-0210-Kfiling · viewer · series
11operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$6.7M2026-06-302026-08-1410-Qfiling · viewer · series
12operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$2.5M2026-03-312026-05-1510-Qfiling · viewer · series
13operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$8.9M2025-09-302026-03-0610-Q/Afiling · viewer · series
14operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$5.2M2025-06-302026-08-1410-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.